804 related articles for article (PubMed ID: 25425467)
1. Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer.
Magee MS; Snook AE
Discov Med; 2014 Nov; 18(100):265-71. PubMed ID: 25425467
[TBL] [Abstract][Full Text] [Related]
2. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
3. Establishing guidelines for CAR-T cells: challenges and considerations.
Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?
Alonso-Camino V; Harwood SL; Álvarez-Méndez A; Alvarez-Vallina L
Biochem Soc Trans; 2016 Apr; 44(2):406-11. PubMed ID: 27068947
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
6. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cell therapy: toxicity and the relevance of preclinical models.
Kalaitsidou M; Kueberuwa G; Schütt A; Gilham DE
Immunotherapy; 2015; 7(5):487-97. PubMed ID: 26065475
[TBL] [Abstract][Full Text] [Related]
8. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M
Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551
[TBL] [Abstract][Full Text] [Related]
10. [Risk and solutions to chimeric antigen receptor-engineered T cell-based cancer immunotherapy].
Zhang MM; Jia DF; Diao Y
Yao Xue Xue Bao; 2016 Jul; 51(7):1032-8. PubMed ID: 29896949
[TBL] [Abstract][Full Text] [Related]
11. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T-cell therapy to target hematologic malignancies.
Kenderian SS; Ruella M; Gill S; Kalos M
Cancer Res; 2014 Nov; 74(22):6383-9. PubMed ID: 25371415
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
15. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
Shirasu N; Kuroki M
Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
[TBL] [Abstract][Full Text] [Related]
17. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.
Gross G; Eshhar Z
Annu Rev Pharmacol Toxicol; 2016; 56():59-83. PubMed ID: 26738472
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
